CD1C and melanoma: Though large clinical trials are needed to define which DC subsets provide optimal therapeutic efficacy in particular settings, early trials with plasmacytoid DC (pDC) and CD1c+ myeloid DC (mDC) have both shown promise in melanoma patients.